Clinical Utility of KRAS and BRAF Mutations in a Cohort of Patients With Colorectal Neoplasms Submitted for Microsatellite Instability Testing
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another retrospective study, in which KRAS was identified through allele-specific polymerase chain reaction on paraffin-embedded tumor specimens, patients with KRAS G12C and KRAS G12S had the highest 2-year OS rates (both 100%); the OS rates were lower in those with other KRASm (OS range, 34% to 87%) and KRASwt (OS, 85%).61”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [61]
In the citing paper
“In contrast to these reports, 2 studies noted that the clinical outcomes in patients with KRAS G12C were either similar or superior to the outcomes observed in patients with other KRASm.”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“30% to 45% in previous studies.(7,9,14,26-32,34,39,40) This may result from the increased sensitivity of allele-specific PCR over that of dideoxy sequencing, or it may also suggest variation in tumor sampling or sample bias.”
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 1×
“An initiating step in the stimulated EGFR pathway is activation of Kirsten ras (KRAS), a guanosine triphosphatase (GTPase) that is activated through binding of guanosine triphosphate (GTP), which subsequently stimulates the serine/threonine kinase BRAF, triggering the MAPK/ERK pathway.(5) KRAS gene mutations are thoug…”
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., Nakagawa, H., Sotamaa, K., Prior, T. W., Westman, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043146 · Cited by 1,408 · cited 2×
“In a screening study for Lynch syndrome, 10 of 23 patients with mutated MMR enzymes presented with tumors in the left colon or rectum.(18) Although our population was enhanced for younger patients because of specimen collection methods, the number of patients with MSI-H tumors in the left colon or rectum suggests that…”
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 2×
“Clinical Colorectal Cancer September 2013 previous data suggesting that these mutations are typically mutually exclusive.(8,34,35)”
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748
Pathologic Predictors of Microsatellite Instability in Colorectal Cancer
Greenson, J. K., Huang, S.-C., Herron, C., Moreno, V., Bonner, J. D., Tomsho, L. P., Ben-Izhak, O., Cohen, H. I., Trougouboff, P., Bejhar, J., et al. (2009) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31817ec2b1 · Cited by 286
Peeters, M., Douillard, J.-Y., Van Cutsem, E., Siena, S., Zhang, K., Williams, R., & Wiezorek, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1492 · Cited by 232 · cited 1×
“G12A mutation to be a negative prognostic factor for OS in the BSC arm.(46) Because KRAS p.”
Research works printed but not linked: 41
- Fearon, 1990, A genetic model for colorectal tumorigenesis, Cell, 61, 759, 10.1016/0092-8674(90)90186-I · DOI · Paper page
- de la Chapelle, 2010, Clinical relevance of microsatellite instability in colorectal cancer, J Clin Oncol, 28, 3380, 10.1200/JCO.2009.27.0652 · DOI · Paper page
- Walther, 2008, Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis, Gut, 57, 941, 10.1136/gut.2007.135004 · DOI · Paper page
- Span, 1996, A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients, Int J Cancer, 69, 241, 10.1002/(SICI)1097-0215(19960621)69:3<241::AID-IJC15>3.0.CO;2-A · DOI · Paper page
- Bazan, 2002, Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype, Ann Oncol, 13, 1438, 10.1093/annonc/mdf226 · DOI · Paper page
- Karapetis, 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med, 359, 1757, 10.1056/NEJMoa0804385 · DOI · Paper page
- Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
- Wang, 2003, BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair, Cancer Res, 63, 5209
- Deng, 2004, BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer, Clin Cancer Res, 10, 191, 10.1158/1078-0432.CCR-1118-3 · DOI · Paper page
- Khambata-Ford, 2007, Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab, J Clin Oncol, 25, 3230, 10.1200/JCO.2006.10.5437 · DOI · Paper page
- Lang, 2011, Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF, J Mol Diagn, 13, 23, 10.1016/j.jmoldx.2010.11.007 · DOI
- Sundstrom, 2010, KRAS analysis in colorectal carcinoma: analytical aspects of pyrosequencing and allele-specific PCR in clinical practice, BMC Cancer, 10, 660, 10.1186/1471-2407-10-660 · DOI · Paper page
- Sinicrope, 2009, Clinical implications of microsatellite instability in sporadic colon cancers, Curr Opin Oncol, 21, 369, 10.1097/CCO.0b013e32832c94bd · DOI · Paper page
- Edelmann, 1997, Mutation in the mismatch repair gene Msh6 causes cancer susceptibility, Cell, 91, 467, 10.1016/S0092-8674(00)80433-X · DOI · Paper page
- Lecomte, 2002, Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis, Int J Cancer, 100, 542, 10.1002/ijc.10526 · DOI · Paper page
- Takeda, 1993, Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA), Hum Mutat, 2, 112, 10.1002/humu.1380020209 · DOI
- Finkelstein, 1993, Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis, Arch Surg, 128, 526, 10.1001/archsurg.1993.01420170056008 · DOI · Paper page
- Finkelstein, 1993, Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type, Cancer, 71, 3827, 10.1002/1097-0142(19930615)71:12<3827::AID-CNCR2820711207>3.0.CO;2-N · DOI · Paper page
- Zhao, 2008, Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1, Gene, 423, 188, 10.1016/j.gene.2008.07.014 · DOI
- Oliveira, 2004, Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status, Hum Mol Genet, 13, 2303, 10.1093/hmg/ddh238 · DOI · Paper page
- Zlobec, 2010, Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer, Int J Cancer, 127, 2569, 10.1002/ijc.25265 · DOI · Paper page
- Benhattar, 1993, Prognostic significance of K-ras mutations in colorectal carcinoma, Gastroenterology, 104, 1044, 10.1016/0016-5085(93)90272-E · DOI · Paper page
- Samowitz, 2005, Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers, Cancer Res, 65, 6063, 10.1158/0008-5472.CAN-05-0404 · DOI · Paper page
- Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 · DOI · Paper page
- Loupakis, 2009, KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer, Br J Cancer, 101, 715, 10.1038/sj.bjc.6605177 · DOI · Paper page
- Andreyev, 2001, Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study, Br J Cancer, 85, 692, 10.1054/bjoc.2001.1964 · DOI · Paper page
- Farina-Sarasqueta, 2010, The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients, Ann Oncol, 21, 2396, 10.1093/annonc/mdq258 · DOI · Paper page
- Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, 366, 883, 10.1056/NEJMoa1113205 · DOI · Paper page
- Ogino, 2009, KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803, Clin Cancer Res, 15, 7322, 10.1158/1078-0432.CCR-09-1570 · DOI · Paper page
- Poehlmann, 2007, K-ras mutation detection in colorectal cancer using the pyrosequencing technique, Pathol Res Pract, 203, 489, 10.1016/j.prp.2007.06.001 · DOI
- Miyaki, 2004, Both BRAF and KRAS mutations are rare in colorectal carcinomas from patients with hereditary nonpolyposis colorectal cancer, Cancer Lett, 211, 105, 10.1016/j.canlet.2004.01.027 · DOI
- Su, 1986, Escherichia coli mutS-encoded protein binds to mismatched DNA base pairs, Proc Natl Acad Sci U S A, 83, 5057, 10.1073/pnas.83.14.5057 · DOI · Paper page
- Bouzourene, 2000, p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer, Eur J Cancer, 36, 1008, 10.1016/S0959-8049(00)00036-8 · DOI
- De Roock, 2010, Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab, JAMA, 304, 1812, 10.1001/jama.2010.1535 · DOI · Paper page
- Moerkerk, 1994, Type and number of Ki-ras point mutations relate to stage of human colorectal cancer, Cancer Res, 54, 3376
- He, 2009, PIK3CA mutations predict local recurrences in rectal cancer patients, Clin Cancer Res, 15, 6956, 10.1158/1078-0432.CCR-09-1165 · DOI · Paper page
- Samowitz, 2009, Microsatellite instability and survival in rectal cancer, Cancer Causes Control, 20, 1763
- Kalady, 2009, Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas, Dis Colon Rectum, 52, 1039, 10.1007/DCR.0b013e31819edbd4 · DOI
- Gaedcke, 2010, KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy, Radiother Oncol, 94, 76, 10.1016/j.radonc.2009.10.001 · DOI
- Chou, 2010, Microsatellite instability screening should be done for right-sided colon cancer patients less than 60 years of age, Int J Colorectal Dis, 25, 47, 10.1007/s00384-009-0815-y · DOI
- Hoogerbrugge, 2003, Very low incidence of microsatellite instability in rectal cancers from families at risk for HNPCC, Clin Genet, 63, 64, 10.1034/j.1399-0004.2003.630110.x · doi:10.1034/j.1399-0004.2003.630110.x
Cited by
Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer
Coppedè, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i4.943 · Cited by 264
Strickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P. (2023) · The Oncologist · doi:10.1093/oncolo/oyad138 · Cited by 54
Metadata
- Authors
- Cushman-Vokoun, A. M., Stover, D. G., Zhao, Z., Koehler, E. A., Berlin, J. D., & Vnencak-Jones, C. L.
- Venue
- Clinical Colorectal Cancer
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 12
- Issue
- 3
- Pages
- 168-178
- ISSN
- 1533-0028
- Cited by
- 24
- References
- 10
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.